SLS peer analysis
SELLAS Life Sciences (SLS) against its competitors: price, today's move, 1-year return and market value side by side.
SLS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AAPG Ascentage Pharma | $14.46 | -2.85% | -60.35% | – |
| AVBP ArriVent BioPharma | $13.86 | -6.83% | -24.99% | – |
| CBIO Crescent Biopharma | $13.48 | -4.19% | 7.75% | $500.74M |
| CCCC C4 Therapeutics | $3.37 | 2.12% | 36.99% | – |
| IDYA IDEAYA Biosciences | $31.43 | -1.64% | -0.52% | $3.08B |
| IMNM Immunome | $19.41 | 6.56% | 21.43% | – |
| INCY Incyte | $119.04 | -1.12% | 28.57% | $24.54B |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| NRIX Nurix Therapeutics | $25.77 | -3.84% | 101.64% | – |
| PRLD Prelude Therapeutics | $3.88 | -5.37% | 147.13% | – |
| SLS SELLAS Life Sciences | $8.66 | -10.49% | 353.66% | $1.95B |
- SLS's peers: AAPG (Ascentage Pharma), AVBP (ArriVent BioPharma), CBIO (Crescent Biopharma), CCCC (C4 Therapeutics), IDYA (IDEAYA Biosciences), IMNM (Immunome), INCY (Incyte), MGNX (MacroGenics).
Updated 2026-11-02 17:13 UTC